Drug intelligence / Profile preview

D150 + D759

Development stage: Preclinical
Lead developer: CKD Research
Modality: Small Molecules
Administration: Oral

Overview

D150 + D759 is a fixed-dose combination comprising two distinct pharmaceutical agents under the code names D150 and D759. Both appear to be investigational or clinical-stage compounds, without established generic or commercial names. Clinical trials have studied this combination, often alongside other agents such as D745, to evaluate their pharmacokinetics, drug-drug interactions, and safety profile in healthy volunteers. The molecular targets, mechanisms of action, and intended therapeutic indications of D150 and D759 are not publicly identified in authoritative sources.

Other names: D759 + D150

Beyond the preview

Go deeper on D150 + D759.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D150 + D759.

Explore the full profile